PO No :PO3262631875-644

Name : Mr.PRITHVI SINGH CHAUHAN Client Name : TATA 1MG OKHLA

Age/Gender : 57/Male Registration Date : 05/Jul/2024 03:31PM
Patient ID : OKH1421033 Collection Date : 05/Jul/2024 07:09AM
Barcode ID/Order ID : D5173585 / 9978864 Sample Receive Date : 06/Jul/2024 10:50AM
Referred By : Dr.NA Report Status : Final Report
Sample Type : Serum Report Date : 06/Jul/2024 12:13PM

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method

Lipid Profile
Cholesterol - Total 161 mg/dL Desirable <200, Enzymatic
Borderline High 200-239,
High >=240
Triglycerides 248 mg/dL Normal: <150, GPO
Borderline: 150 - 199,
High:200-499,
Very High>=500
Cholesterol - HDL 30 mg/dL Undesirable/high risk Elimination/catalase
<=40mg/dL
Desirable/low
risk>=60mg/dl
Cholesterol - LDL 81 mg/dL Desirable: <100 Calculated
Above desirable: 100 -
129
Borderline high : 130 -
159
High : 160 - 189
Very high : >=190
Cholesterol- VLDL 50 mg/dl <30 Calculated
Cholesterol : HDL Cholesterol 5.3 Ratio Desirable : 3.5-4.5 Calculated
High Risk : >5
LDL : HDL Cholesterol 2.66 Ratio Desirable : 2.5-3.0 Calculated
High risk : >3.5
Non HDL Cholesterol 131 mg/dl Desirable:< 130, Calculated
Above Desirable:130 -
159,
Borderline High:160 -
189,
High:190 - 219,
Very High: >= 220

Comment:

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 1 of 3
PO No :PO3262631875-644

Name : Mr.PRITHVI SINGH CHAUHAN Client Name : TATA 1MG OKHLA

Age/Gender : 57/Male Registration Date : 05/Jul/2024 03:31PM
Patient ID : OKH1421033 Collection Date : 05/Jul/2024 07:09AM
Barcode ID/Order ID : D5173585 / 9978864 Sample Receive Date : 06/Jul/2024 10:50AM
Referred By : Dr.NA Report Status : Final Report
Sample Type : Serum Report Date : 06/Jul/2024 12:13PM

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
•Lipid profile measurements in the same patient can show physiological & analytical variations. It is recommended that 3 serial
samples 1 week apart may be tested.
•Indians are at a high risk of developing atherosclerotic cardiovascular disease (ASCVD); at a much earlier age and more severe
with high mortality. Dyslipidemia (abnormal lipid profile) is the major risk factor and found in almost 80% Indians.
•Total cholesterol is the total amount of cholesterol in blood comprising of HDL, LDL-C, and VLDL.
•LDL Cholesterol (LDL-C) or “bad”cholesterol contributes most significantly to atherosclerosis leading to heart disease or
stroke and is the primary target for reducing risk for cardiovascular disease.
•High-density lipoprotein (HDL) or “good” cholesterol can lower risk of heart disease and stroke.
•Triglyceride (TG) level also plays a major role in CVD. Indians are more prone to Atherogenic dyslipidemia, a condition
associated with high TG, low HDL-C and high LDL-C; this is associated with diabetes, metabolic syndrome and insulin resistance.
Hence high triglyceride levels also need to be treated.
•Non-HDL-Cholesterol (Non-HDLC) measures all plaque forming lipoproteins (e.g. remnants, LDL-C, VLDL, Lp(a), Apo-B).
Monitoring of Non-HDLC is important in patients with high TG (e.g. diabetics, obese persons) and those already on statin
therapy.
•Lipid Association of India (LAI-2020) recommends:-

Screening of all Indians above the age of 20 years for CVD risk factors, esp. lipid profile.
Identification of Risk factors: Age (male ≥45 years, female ≥55 years); Family h/o heart disease at younger age (<55 yrs
in males, <65 yrs in female), Smoking/tobacco use, High blood pressure, Low HDL (males <40 mg/dl and females
<50mg/dl).
Fasting lipid profile is not mandatory for screening. Both fasting and non-fasting lipid profiles are equally important for
managing Indian patients.
Non-HDLC should be calculated in every subject. LAI recommends LDL-C as the primary target and Non-HDLC as the co-
primary target for initiating drug therapy.
Lifestyle modifications are of first and foremost importance for management and prevention of dyslipidemia. Among low
risk groups, treatment is started only after 3 months of lifestyle changes.
Testing for Apolipoprotein B, hsCRP, Lp(a ) should be considered for patients in moderate risk group.
Newer treatment goals based on Risk Groups and values of LDL-C and Non-HDLC

New treatment goals by Lipid Association of India (2020)

CONSIDER THERAPY (cut-off level) TREATMENT GOALS
Risk groups LDL-C (mg/dL) Non-HDLC (mg/dL) LDL-C (mg/dL) Non-HDLC (mg/dL)
<50 <80
Extreme Risk Gp Cat. A ≥50 ≥80
(Optional ≤30) (Optional ≤60)
Extreme Risk Gp Cat. B >30 >60 ≤30 ≤60
Very High Risk ≥50 ≥80 <50 <80
High Risk ≥70 ≥100 <70 <100
Moderate Risk ≥100 ≥130 <100 <130
Low risk ≥130* ≥160* <100 <130
*After an adequate non-pharmacological intervention for at least 3 months

•As per NCEP Expert Panel (2011) guidelines, universal screening for dyslipidemia is recommended for children between 9
- 11 yrs (repeat at 17-21 yrs). Screening is not recommended before the age of 2yrs. Above the age of 2 yrs, selective screening
is done in children with family history of premature CVD or risk factors like obesity, diabetes, and hypertension.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 2 of 3
 PO No :PO3262631875-644

Name : Mr.PRITHVI SINGH CHAUHAN Client Name : TATA 1MG OKHLA

Age/Gender : 57/Male Registration Date : 05/Jul/2024 03:31PM
Patient ID : OKH1421033 Collection Date : 05/Jul/2024 07:09AM
Barcode ID/Order ID : D5173585 / 9978864 Sample Receive Date : 06/Jul/2024 10:50AM
Referred By : Dr.NA Report Status : Final Report
Sample Type : Serum Report Date : 06/Jul/2024 12:13PM

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
Note: Reference Interval as per National Cholesterol Education Program (NCEP) Report.

*** End Of Report ***

Conditions of Laboratory Testing & Reporting:
Test results released pertain to the sample, as received. Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should
be clinically correlated by the interpreting clinician. Result delays may happen because of unforeseen or uncontrollable circumstances. Test report
may vary depending on the assay method used. Test results may show inter-laboratory variations. Test results are not valid for medico-legal
purposes. Please mail your queries related to test results to Customer Care mall ID care@1mg.com

Disclaimer: Results relate only to the sample received. Test results marked "BOLD" indicate abnormal results i.e. higher or lower than normal. All
lab test results are subject to clinical interpretation by a qualified medical professional. This report cannot be used for any medico-legal purposes.
Partial reproduction of the test results is not permitted. Also, TATA 1mg Labs is not responsible for any misinterpretation or misuse of the
information. The test reports alone may not be conclusive of the disease/condition, hence clinical correlation is necessary. Reports should be
vetted by a qualified doctor only.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 3 of 3
 Ensuring accuracy IN every single report
Following a 3-step review process:

Advanced systems & Experienced lab experts Each report undergoes

cutting-edge technology analyze and technicians conduct rigorous medical scrutiny & is
results with precision comprehensive reviews signed off by a doctor

Have concerns regarding the report?

Reach out to our care team at care@1mg.com
or chat with us
CONNECT NOW >

Accurate Testing, Assured Quality: Diagnostics Precision

Stringent quality control Cutting-edge technology Experienced lab staff

Measures meeting Robust healthcare systems 30+ medical professionals
international norms of safety equipped with calibrated & with a collective
guidelines well-maintained machinery experience of 200+ years

Verified test procedures External assessments Trained phlebotomists

Highly standardized test Thorough third-party Ensuring smooth sample
procedures following CLSI* assessment by authorized collection experience &
guidelines experts pre-analytical precision

Claim FREE doctor consultation

Watch how
Consult top doctors from
the comfort of your home
we take care of
your sample
SCHEDULE NOW>

Get Second Opinion Order Medicines EXPLORE NOW >

Explore Financial Need Help?

Book Lab Tests
Support & more 1800-102-1618

*Clinical & Laboratory Standards Institute T&C Apply